Filing Details

Accession Number:
0001628280-24-052603
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-12-30 19:41:52
Reporting Period:
2024-12-02
Accepted Time:
2024-12-30 19:41:52
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1087294 Cumberland Pharmaceuticals Inc CPIX Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1695580 Kenneth Krogulski 1600 West End Ave., Suite 1300
Nashville TN 37203
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-12-02 415 $1.33 272,042 No 5 P Direct
Common Stock Acquisiton 2024-12-03 415 $1.26 272,457 No 5 P Direct
Common Stock Acquisiton 2024-12-04 415 $1.22 272,872 No 5 P Direct
Common Stock Acquisiton 2024-12-05 350 $1.20 273,222 No 5 P Direct
Common Stock Acquisiton 2024-12-06 415 $1.20 273,637 No 5 P Direct
Common Stock Acquisiton 2024-12-09 415 $1.25 274,052 No 5 P Direct
Common Stock Acquisiton 2024-12-10 197 $2.48 274,249 No 5 P Direct
Common Stock Acquisiton 2024-12-11 197 $2.29 274,446 No 5 P Direct
Common Stock Acquisiton 2024-12-12 197 $2.19 274,643 No 5 P Direct
Common Stock Acquisiton 2024-12-13 197 $2.33 274,840 No 5 P Direct
Common Stock Acquisiton 2024-12-16 312 $2.21 275,152 No 5 P Direct
Common Stock Acquisiton 2024-12-17 312 $2.12 275,464 No 5 P Direct
Common Stock Acquisiton 2024-12-18 312 $2.19 275,776 No 5 P Direct
Common Stock Acquisiton 2024-12-19 266 $2.33 276,042 No 5 P Direct
Common Stock Acquisiton 2024-12-20 301 $2.35 276,343 No 5 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 5 P Direct
No 5 P Direct
No 5 P Direct
No 5 P Direct
No 5 P Direct
No 5 P Direct
No 5 P Direct
No 5 P Direct
No 5 P Direct
No 5 P Direct
No 5 P Direct
No 5 P Direct
No 5 P Direct
No 5 P Direct
No 5 P Direct
Footnotes
  1. The reported purchases occurred automatically pursuant to a Rulo10b5-1 trading plan adopted by the reporting person on March 13, 2024.